These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1447395)

  • 1. A comparison of regulatory approval times for new chemical entities in Australia, Canada, Sweden, the United Kingdom, and the United States.
    Pieterson EA
    J Clin Pharmacol; 1992 Oct; 32(10):889-96. PubMed ID: 1447395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?
    Rawson NS
    Clin Ther; 2003 Apr; 25(4):1230-47. PubMed ID: 12809970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
    Rawson NS; Kaitin KI
    Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States.
    Rawson NS
    Can J Clin Pharmacol; 2002; 9(2):73-8. PubMed ID: 12172587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of hormone replacement therapy products in Canada.
    Brown TE; Lalonde AB; Fortin C; Lea R; Azzarello D
    J Obstet Gynaecol Can; 2004 Jun; 26(6):560-3. PubMed ID: 15193200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drug approval times and safety warnings in the United States and Canada, 1992-2011.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2013; 20(2):e67-81. PubMed ID: 23650206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The timeliness of new drug approvals in Canada.
    Rawson NS
    Int J Health Serv; 1995; 25(1):153-65; discussion 167-71. PubMed ID: 7794387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.
    Ezeife DA; Truong TH; Heng DY; Bourque S; Welch SA; Tang PA
    Cancer; 2015 May; 121(10):1688-93. PubMed ID: 25604014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
    Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
    Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian, European and United States new drug approval times now relatively similar.
    Rawson NSB
    Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.
    Morgan SG; McMahon M; Mitton C; Roughead E; Kirk R; Kanavos P; Menon D
    Health Aff (Millwood); 2006; 25(2):337-47. PubMed ID: 16522575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory approval time for hormonal contraception in Canada, the United States and the United Kingdom, 2000-2015: a retrospective data analysis.
    Troskie C; Soon JA; Albert AY; Norman WV
    CMAJ Open; 2016; 4(4):E654-E660. PubMed ID: 28018878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug approval times.
    Lexchin J; Mintzes B
    CMAJ; 2000 Jun; 162(13):1803-4. PubMed ID: 10906911
    [No Abstract]   [Full Text] [Related]  

  • 18. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.
    Bakke OM; Manocchia M; de Abajo F; Kaitin KI; Lasagna L
    Clin Pharmacol Ther; 1995 Jul; 58(1):108-17. PubMed ID: 7628177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.